Glatiramer Acetate Injection, Solution
NDC Package 0832-6085-12

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Glatiramer Acetate (glatiramer acetate injection) injection is a medication used to treat multiple sclerosis (MS). This formulation utilizes a injection, solution delivery system. Marketed by Upsher-smith Laboratories, Llc, this product is identified by NDC 0832-6085 and is authorized under FDA application ANDA214741.

Identification & Billing

NDC Package Code
0832-6085-12
Package Description
12 SYRINGE, GLASS in 1 CARTON / 1 mL in 1 SYRINGE, GLASS (0832-6085-89)
Product Code
11-Digit Billing Format
00832608512
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Glatiramer Acetate
Non-Proprietary Name
Glatiramer Acetate Injection
Substance Name
Glatiramer Acetate
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
Usage Information
This medication is used to treat multiple sclerosis (MS). It is a protein that is thought to work by preventing your immune system from attacking the nerves in your brain and spinal cord. This effect can decrease the number of periods of disease worsening (relapses) and prevent or delay disability. It is not a cure for MS.

Regulatory & Marketing

Labeler Name
Upsher-smith Laboratories, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA214741
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-23-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

Source: PDAC
INJECTION, GLATIRAMER ACETATE, 20 MG
HCPCS Dosage 20 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0832-6085-12 identifies a specific commercial package of 12 syringe, glass in 1 carton / 1 ml in 1 syringe, glass (0832-6085-89) of Glatiramer Acetate, a human prescription drug labeled by Upsher-smith Laboratories, Llc. This injection, solution is formulated for subcutaneous use and contains glatiramer acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Upsher-smith Laboratories, Llc on January 23, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to treat multiple sclerosis (MS). It is a protein that is thought to work by preventing your immune system from attacking the nerves in your brain and spinal cord. This effect can decrease the number of periods of disease worsening (relapses) and prevent or delay disability. It is not a cure for MS.

How is this Upsher-smith Laboratories, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00832608512. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0832-6085-12
11-Digit CMS (5-4-2)
00832-6085-12

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.